Bruker Research Development vs Total Other Income Expense Net Analysis
BRKR Stock | USD 80.97 0.38 0.47% |
Bruker financial indicator trend analysis is way more than just evaluating Bruker prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bruker is a good investment. Please check the relationship between Bruker Research Development and its Total Other Income Expense Net accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bruker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. To learn how to invest in Bruker Stock, please use our How to Invest in Bruker guide.
Research Development vs Total Other Income Expense Net
Research Development vs Total Other Income Expense Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bruker Research Development account and Total Other Income Expense Net. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Bruker's Research Development and Total Other Income Expense Net is 0.54. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Total Other Income Expense Net in the same time period over historical financial statements of Bruker, assuming nothing else is changed. The correlation between historical values of Bruker's Research Development and Total Other Income Expense Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Bruker are associated (or correlated) with its Total Other Income Expense Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Other Income Expense Net has no effect on the direction of Research Development i.e., Bruker's Research Development and Total Other Income Expense Net go up and down completely randomly.
Correlation Coefficient | 0.54 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Research Development
Total Other Income Expense Net
Most indicators from Bruker's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bruker current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bruker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. To learn how to invest in Bruker Stock, please use our How to Invest in Bruker guide.At this time, Bruker's Selling General Administrative is relatively stable compared to the past year. As of 04/27/2024, Sales General And Administrative To Revenue is likely to grow to 0.26, while Tax Provision is likely to drop slightly above 82.4 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.2B | 1.3B | 1.5B | 1.6B | Total Revenue | 2.4B | 2.5B | 3.0B | 3.1B |
Bruker fundamental ratios Correlations
Click cells to compare fundamentals
Bruker Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bruker fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.8B | 3.0B | 3.7B | 3.6B | 4.2B | 4.5B | |
Total Stockholder Equity | 917.1M | 975.6M | 1.1B | 1.1B | 1.4B | 1.4B | |
Non Current Assets Total | 975.2M | 1.1B | 1.2B | 1.5B | 2.1B | 2.2B | |
Non Currrent Assets Other | 16.8M | 39.6M | 70.8M | (99.8M) | 175.7M | 184.5M | |
Other Assets | 77.3M | 180M | 160.9M | 208.9M | 240.2M | 252.2M | |
Common Stock Shares Outstanding | 156.6M | 154.6M | 152.9M | 149.4M | 147.2M | 143.8M | |
Liabilities And Stockholders Equity | 2.8B | 3.0B | 3.7B | 3.6B | 4.2B | 4.5B | |
Non Current Liabilities Total | 1.2B | 1.3B | 1.6B | 1.6B | 1.6B | 1.7B | |
Other Stockholder Equity | (333.8M) | (436.3M) | (568.4M) | (816.8M) | (954.3M) | (906.6M) | |
Total Liab | 1.9B | 2.1B | 2.6B | 2.5B | 2.8B | 3.0B | |
Short Long Term Debt Total | 860.3M | 891.5M | 1.3B | 1.2B | 1.4B | 1.4B | |
Other Current Liab | 388.8M | 467.6M | 481.2M | 487.1M | 454.9M | 260.9M | |
Total Current Liabilities | 645.6M | 793.6M | 938.5M | 913.8M | 1.2B | 1.3B | |
Property Plant And Equipment Net | 371.7M | 462.9M | 406.1M | 487M | 691.4M | 726.0M | |
Net Debt | 182M | 209.7M | 266M | 573.7M | 891.3M | 935.9M | |
Retained Earnings | 1.3B | 1.4B | 1.7B | 1.9B | 2.3B | 2.4B | |
Accounts Payable | 118.4M | 134.6M | 147.4M | 182.3M | 202.7M | 212.8M | |
Cash | 678.3M | 681.8M | 1.1B | 645.5M | 488.3M | 311.3M | |
Cash And Short Term Investments | 684.9M | 731.8M | 1.2B | 645.5M | 488.3M | 358.2M | |
Net Receivables | 362.2M | 335.3M | 416.9M | 472.7M | 621.8M | 652.9M | |
Inventory | 577.2M | 692.3M | 710.1M | 803.7M | 968.3M | 1.0B | |
Other Current Assets | 172M | 165.5M | 176.6M | 202.6M | 85.8M | 113.8M | |
Property Plant And Equipment Gross | 371.7M | 462.9M | 406.1M | 487M | 1.2B | 1.3B | |
Total Current Assets | 1.8B | 1.9B | 2.5B | 2.1B | 2.2B | 1.1B | |
Accumulated Other Comprehensive Income | (25.5M) | 3.7M | (8.2M) | 14.8M | 6M | 5.7M | |
Short Term Debt | 500K | 2.2M | 112.4M | 18.7M | 144.5M | 151.7M | |
Intangible Assets | 603.5M | 229.1M | 211.8M | 270.9M | 330.5M | 196.5M | |
Other Liab | 311M | 389.4M | 404.9M | 318.2M | 365.9M | 384.2M | |
Long Term Debt | 812.8M | 842.3M | 1.2B | 1.2B | 1.2B | 1.2B | |
Short Term Investments | 0.0 | 6.6M | 50M | 100M | 12M | 11.4M | |
Property Plant Equipment | 306.1M | 395.5M | 406.1M | 487M | 560.1M | 588.1M | |
Current Deferred Revenue | 137.9M | 189.2M | 197.5M | 225.7M | 400M | 420M | |
Treasury Stock | (543.8M) | (667M) | (820.3M) | (1.1B) | (976.5M) | (927.7M) | |
Good Will | 293M | 320.4M | 339.5M | 457.6M | 582.6M | 611.7M | |
Net Tangible Assets | 491.5M | 509.6M | 312.5M | 1.2B | 1.4B | 1.5B | |
Noncontrolling Interest In Consolidated Entity | 10.3M | 13.1M | 14.1M | 11.9M | 13.7M | 8.2M | |
Retained Earnings Total Equity | 1.3B | 1.4B | 1.7B | 1.9B | 2.2B | 2.3B | |
Long Term Debt Total | 812.8M | 842.3M | 1.2B | 1.2B | 1.4B | 1.4B |
Pair Trading with Bruker
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bruker position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bruker will appreciate offsetting losses from the drop in the long position's value.Moving together with Bruker Stock
0.89 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
0.83 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
0.61 | ENVB | Enveric Biosciences Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Bruker could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bruker when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bruker - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bruker to buy it.
The correlation of Bruker is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bruker moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bruker moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bruker can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bruker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. To learn how to invest in Bruker Stock, please use our How to Invest in Bruker guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Bruker Stock analysis
When running Bruker's price analysis, check to measure Bruker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bruker is operating at the current time. Most of Bruker's value examination focuses on studying past and present price action to predict the probability of Bruker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bruker's price. Additionally, you may evaluate how the addition of Bruker to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Global Correlations Find global opportunities by holding instruments from different markets | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Bruker's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bruker. If investors know Bruker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bruker listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.127 | Dividend Share 0.2 | Earnings Share 2.9 | Revenue Per Share 20.249 | Quarterly Revenue Growth 0.206 |
The market value of Bruker is measured differently than its book value, which is the value of Bruker that is recorded on the company's balance sheet. Investors also form their own opinion of Bruker's value that differs from its market value or its book value, called intrinsic value, which is Bruker's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bruker's market value can be influenced by many factors that don't directly affect Bruker's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bruker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bruker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bruker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.